Aeglea, which is working on treatments for metabolic diseases, has now raised $56m in just over a year, after closing a series B round co-led by Novartis and Eli Lilly.
US-based biopharmaceutical company Aeglea Biotherapeutics closed a $44m series B round co-led by the corporate venturing units of pharmaceutical firms Eli Lilly and Novartis.
Lilly Ventures and Novartis Venture Fund were joined by UT Horizon Fund, OrbiMed, Jennison Associates, Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments.
Aeglea will use the capital to support the advancement of its engineered human enzymes, which are being developed to combat metabolic diseases characterised by excessive levels of amino…
